首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1143959篇
  免费   78780篇
  国内免费   2129篇
耳鼻咽喉   15288篇
儿科学   34065篇
妇产科学   30527篇
基础医学   156590篇
口腔科学   29037篇
临床医学   97152篇
内科学   217515篇
皮肤病学   18755篇
神经病学   95374篇
特种医学   47589篇
外国民族医学   174篇
外科学   183435篇
综合类   28664篇
现状与发展   3篇
一般理论   335篇
预防医学   92867篇
眼科学   25653篇
药学   81047篇
中国医学   2345篇
肿瘤学   68453篇
  2018年   32076篇
  2017年   25545篇
  2016年   29413篇
  2015年   10382篇
  2014年   14355篇
  2013年   21463篇
  2012年   35129篇
  2011年   51327篇
  2010年   36195篇
  2009年   28278篇
  2008年   49397篇
  2007年   55468篇
  2006年   30742篇
  2005年   32906篇
  2004年   33898篇
  2003年   34402篇
  2002年   31176篇
  2001年   37044篇
  2000年   37759篇
  1999年   31885篇
  1998年   10620篇
  1997年   9909篇
  1996年   9504篇
  1995年   9028篇
  1994年   8673篇
  1992年   27316篇
  1991年   26761篇
  1990年   26206篇
  1989年   25253篇
  1988年   23743篇
  1987年   23406篇
  1986年   22256篇
  1985年   21650篇
  1984年   17091篇
  1983年   14747篇
  1982年   9815篇
  1981年   9014篇
  1980年   8575篇
  1979年   17256篇
  1978年   12654篇
  1977年   10709篇
  1976年   9834篇
  1975年   10535篇
  1974年   12971篇
  1973年   12460篇
  1972年   11782篇
  1971年   10842篇
  1970年   10422篇
  1969年   10066篇
  1968年   9027篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Cutaneous leiomyomas are rare benign smooth‐muscle tumors. These lesions are distinguished based on their cell of origin and are subclassified as pilar leiomyoma, angioleiomyoma, and genital‐type leiomyoma. Nipple leiomyoma is the least common genital‐type leiomyoma, arising from the dartoic muscle cell of the nipple. Histologic examination of the lesion is necessary for definitive diagnosis, and these uncommon tumors can pose a diagnostic challenge. We describe herein a series of six nipple leiomyomas with a spectrum of histologic appearances.  相似文献   
12.
13.
14.
15.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
16.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
17.
18.
19.
20.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号